Compare SYNX & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYNX | NXL |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | Israel | United States |
| Employees | N/A | 7 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 8.3M |
| IPO Year | 2023 | N/A |
| Metric | SYNX | NXL |
|---|---|---|
| Price | $1.00 | $0.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 106.4K |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.35 | $120.99 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.34 |
| 52 Week High | $2.15 | $2.31 |
| Indicator | SYNX | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 35.56 |
| Support Level | $0.93 | N/A |
| Resistance Level | $1.31 | $0.46 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 21.27 | 18.31 |
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.